Cellestia

Cellestia is a clinical stage R&D company that develops innovative therapies to control and modulate pathogenic gene expression in multiple disease areas by selectively inhibiting transcription factors in the cell nucleus. The company's lead compound, CB-103, has successfully treated patients with multi-drug resistant cancers in Phase 2 trials. Cellestia is advancing a rich R&D pipeline of novel t...